FlexBioTech

Executive Summary

FlexBioTech is a Boston-based diagnostics company developing rapid, low-cost, saliva-based point-of-care tests that aim to deliver PCR-level accuracy for infectious diseases and cancer screening. Founded in 2020, the company leverages proprietary DNA/RNA biomarkers and a portable platform to enable decentralized testing, reducing reliance on centralized laboratories. This approach targets low-resource environments where traditional diagnostic infrastructure is lacking, potentially transforming proactive disease management. The company's core value proposition lies in combining comfort (saliva sampling) with high sensitivity and specificity, addressing a critical gap in diagnostics for both acute infections and chronic conditions like cancer. While still in a private, pre-revenue stage with undisclosed funding, FlexBioTech's technology could disrupt the point-of-care diagnostics market, which is projected to grow significantly. However, the path to commercialization requires successful clinical validation, regulatory clearances, and strategic partnerships to compete with established players.

Upcoming Catalysts (preview)

• TBDClinical data readout for lead infectious disease test60% success
• TBDSeries A funding round to accelerate development70% success
• TBDStrategic partnership with a global health organization or diagnostic distributor50% success